Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Allison Scott

Physician Assistant, Medical Lexington, KY Physician Assistant

NPI 1205239282 CMS profile 10980282

1720 Nicholasville Rd Ste 400, Lexington, KY 40503

Open in the dashboard

General payments

$8,309

178 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Allison Scott of Lexington, KY is reported in the CMS Open Payments database as having received $8,309 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,846 54
2024 General $3,568 70
2023 General $1,468 44
2022 General $231 8
2021 General $196 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allison Scott
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Allison Scott were reported at $2,846. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Allison Scott Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $196 $156 $41–$563 $132
2022 $231 $185 $55–$649 $149
2023 $1,468 $199 $58–$717 $160
2024 $3,568 $206 $62–$740 $164
2025 $2,846 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Atricure, Inc. $2,077 21 payments
  2. AOP Health US, LLC $1,109 2 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $953 30 payments
  4. AstraZeneca Pharmaceuticals LP $803 16 payments
  5. Abbott Laboratories $695 11 payments
  6. E.R. Squibb & Sons, L.L.C. $399 15 payments
  7. Pfizer Inc. $391 21 payments
  8. Inari Medical, Inc. $216 1 payment
  9. Novo Nordisk Inc $199 7 payments
  10. Impulse Dynamics (USA) Inc. $169 2 payments
  11. Other $1,298 52 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,241 175 payments
  2. Travel and Lodging $1,068 3 payments
Products named General payments · program years 2021–2025
  1. SYNERGY ABLATION SYSTEM $1,471 8 payments
  2. Rapiblyk Cardiovascular $1,109 2 payments
  3. Rapiblyk Cardiovascular $1,109 2 payments
  4. LifeVest $953 30 payments
  5. ATRICLIP LAA EXCLUSION SYSTEM $606 13 payments
  6. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $522 3 payments
  7. AtriCure cryoICE cryoSPHERE Cryoablation System $494 2 payments
  8. CARDIOMEMS $446 7 payments
  9. CAMZYOS $342 10 payments
  10. VYNDAQEL $337 17 payments
  11. Other $3,457 106 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,221

Median for Physician Assistant: 241

Drug cost

$144,197

Median for Physician Assistant: $4,110

Branded share of claims

22.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 48 $52,673
Jardiance Empagliflozin Brand 38 $30,571
Xarelto Rivaroxaban Brand 17 $17,966
Entresto Sacubitril/Valsartan Brand 16 $15,923
Farxiga Dapagliflozin Propanediol Brand 13 $12,080
Dofetilide Generic 25 $3,242
Bisoprolol Fumarate Generic 59 $1,267
Metoprolol Succinate Generic 115 $1,142
Ezetimibe Generic 36 $1,009
Bumetanide Generic 46 $962

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$34,276

Medicare's payments for the services billed

Medicare patients

422

Average age 76

Services billed

619

234 women, 188 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Arthritis 59%
Atrial fibrillation 49%
Chronic kidney disease 41%
Heart failure 40%
Diabetes 38%
COPD 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $139
$139 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $116
$116 13 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $107
$107 38 —
VYNDAQEL
  • PFIZER INC. $89
$89 — —
BRILINTA
  • AstraZeneca Pharmaceuticals LP $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record